Oral PCSK9 Inhibitor
搜索文档
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
Businesswire· 2026-03-30 23:45
核心观点 - 在研口服PCSK9抑制剂Enlicitide相比口服非他汀类药物展现出显著更优的低密度脂蛋白胆固醇降低效果 [1] 药物研发进展与临床数据 - Enlicitide是一种在研的口服PCSK9抑制剂 [1] - 该药物在降低低密度脂蛋白胆固醇方面，效果显著优于口服非他汀类药物 [1]
